Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


US EPA to OK oxalic acid for varroa mite control

The US EPA has proposed the approval of oxalic acid dihydrate under an expedited review process for the control of varroa mites in beehives. The application was submitted by the USDA Animal and Plant Health Inspection Service's Bee Research Lab at the request of the EPA's Office of Pesticide Programs (OPP). Oxalic acid was previously registered as an antimicrobial pesticide and the OPP has in-house data on human health, environmental fate and ecotoxicology, the Agency points out. It cites President Barack Obama's June 2014 memorandum to create a federal strategy to promote the health of bees and to expedite the review of products targeting pests harmful to pollinators. The EPA also notes that the application could be expedited through its work sharing agreement with the Canadian authorities as oxalic acid was approved for varroa mite control in Canada in 2010. The normal 24-month schedule for a registration decision would make the due date in December 2016. But the EPA is seeking public comment on its proposed approval by March 6th 2015.



What to read next




Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts